Search

Publications

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.

Read more

Meet Willem Fibbe, our volunteer of the month

Can you tell us what you do for EHA and when you started?
I have been involved in EHA over a period of twenty years, starting as counselor from 2000-2004.

Read more

Meet Willem Fibbe, our volunteer of the month

Can you tell us what you do for EHA and when you started?
I have been involved in EHA over a period of twenty years, starting as counselor from 2000-2004.

Read more

Uptake of CAR T cell therapy in Europe

Feb 05 2019 Posted in Advocacy news Tagged CAR T

Gene (editing) therapy continues to break ground in hematology, showing promising results in tackling severe blood cancers. Yet, its uptake in the European Union is slow, with few patients benefiting from it so far.

Read more

Highlights of Past EHA (HOPE) Latin America 2020

EHA and the Argentinian Society of Hematology (SAH) are very happy to announce that the Highlights of Past EHA (HOPE) Latin America 2020 will take place on November 13, 2020 in a virtual format.

Read more

Do generics of imatinib jeopardize patient safety for the sake of saving money? An experience in Turkish patients.

 

The high cost of tyrosine kinase inhibitors developed for chronic myeloid leukemia is a major concern for the health care payers, especially in countries with restricted resources.

Read more

Meet Helen Papadaki, our January volunteer of the month

Can you tell us what you do for EHA and when you started?
I am currently a Councilor of the EHA Board for the period 2016-2020, chair of the EHA Membership Committee and vice-chair of the Scientific Working Group (SWG) on…

Read more